Full text is available at the source.
Abstract
Obesity is a major risk factor for heart failure with preserved ejection fraction (HFpEF).
- HFpEF is linked to systemic inflammation, neurohormonal activation, and mechanical inhibition due to obesity.
- Treatments for obesity may improve outcomes in patients with HFpEF.
- Sodium-glucose cotransporter 2 inhibitors are effective in enhancing symptoms and quality of life in HFpEF patients while assisting with weight control.
- Glucagon-like peptide-1 receptor agonists may reduce weight loss and improve symptoms and clinical outcomes in those with HFpEF.
- The association between obesity and HFpEF suggests potential directions for future medical therapies targeting this condition.
Simplified